Oppenheimer Maintains Outperform on Capricor Therapeutics, Raises Price Target to $54

Benzinga · 1d ago
Oppenheimer analyst Leland Gershell maintains Capricor Therapeutics (NASDAQ:CAPR) with a Outperform and raises the price target from $22 to $54.